Register Login

CLEARSIDE BIOMEDICAL, INC. (CLSDQ)

SymbolCLSDQ
NameCLEARSIDE BIOMEDICAL, INC.
SectorHEALTH CARE
RegionNorth America
Industry-
Address30005 United States GA 900 North Point Parkway Suite 200
Telephone(678) 270-3631
Fax—
Email—
Websitehttps://clearsidebio.com/
IncorporationUS
Incorporated On—
Employees—
Fiscal Year12/31
Public Since—
ExchangesOTC;NASDAQ
Auditor—
Audit StatusAUDITED
Reporting StatusDark: Alternative Reporting Standard
CIK0001539029
Description

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc.

Additional info from NASDAQ:
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision.

Additional info from OTC:
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc.

No news found.

Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT05891548 Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neov… Phase2 Neovascular Age-related Macular Degeneration Completed 2023-05-31 2024-08-20 ClinicalTrials.gov
NCT05131646 Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CL… — Neovascular Age-related Macular Degeneration Completed 2021-10-08 2023-01-05 ClinicalTrials.gov
NCT04626128 Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following A… Phase1 Neovascular Age-related Macular Degeneration Completed 2020-12-15 2022-10-13 ClinicalTrials.gov
NCT03203447 Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subje… Phase3 Macular Edema Terminated 2018-03-05 2018-12-18 ClinicalTrials.gov
NCT02952001 MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participa… — Uveitis Completed 2017-12-13 2018-05-22 ClinicalTrials.gov
NCT03126786 Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in… Phase2 Diabetic Macular Edema Completed 2017-07-11 2018-04-17 ClinicalTrials.gov
NCT03097315 Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis Phase3 Uveitis Completed 2017-04-04 2018-01-24 ClinicalTrials.gov
NCT02980874 Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Sub… Phase3 Macular Edema Terminated 2017-01-31 2018-12-10 ClinicalTrials.gov
NCT02949024 Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With D… Phase1 Diabetic Macular Edema Completed 2016-11-10 2017-10-17 ClinicalTrials.gov
NCT02956330 Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects… — Macular Edema Completed 2016-11-01 2017-04-12 ClinicalTrials.gov
NCT02595398 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated Wi… Phase3 Uveitis Completed 2015-11-17 2018-01-18 ClinicalTrials.gov
NCT02303184 Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Sub… Phase2 Macular Edema Completed 2015-01-01 2016-03-01 ClinicalTrials.gov
NCT02255032 Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Ed… Phase2 Uveitis Completed 2014-10-01 2016-01-01 ClinicalTrials.gov
NCT01789320 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat… Phase1 Uveitis Completed 2013-02-01 2015-03-01 ClinicalTrials.gov
Total clinical trials: 14
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
triamcinolone acetonide (Triesence®) Other Phase PHASE1 Uveitis COMPLETED NCT01789320
Aflibercept Other Phase PHASE2 Neovascular Age-related Macular Degeneration COMPLETED NCT05891548
CLS-AX Other Phase PHASE2 Neovascular Age-related Macular Degeneration COMPLETED NCT05891548
IVT aflibercept Other Phase PHASE2 Macular Edema COMPLETED NCT02303184
Sham Other Phase PHASE2 Macular Edema COMPLETED NCT02303184
4 mg CLS-TA Other Phase PHASE2 Macular Edema COMPLETED NCT02303184
0.8 mg CLS-TA Other Phase PHASE2 Uveitis COMPLETED NCT02255032
4 mg CLS-TA Other Phase PHASE2 Uveitis COMPLETED NCT02255032
IVT aflibercept Other Phase PHASE3 Macular Edema TERMINATED NCT02980874
suprachoroidal sham Other Phase PHASE3 Macular Edema TERMINATED NCT02980874
suprachoroidal CLS-TA Other Phase PHASE3 Macular Edema TERMINATED NCT02980874
Lucentis or Avastin Other Phase PHASE3 Macular Edema TERMINATED NCT03203447
suprachoroidal sham Other Phase PHASE3 Macular Edema TERMINATED NCT03203447
suprachoroidal CLS-TA Other Phase PHASE3 Macular Edema TERMINATED NCT03203447
SC CLS-TA Other Phase PHASE2 Diabetic Macular Edema COMPLETED NCT03126786
Sham SC Other Phase PHASE2 Diabetic Macular Edema COMPLETED NCT03126786
IVT aflibercept Other Phase PHASE2 Diabetic Macular Edema COMPLETED NCT03126786
SC CLS-TA Other Phase PHASE1 Diabetic Macular Edema COMPLETED NCT02949024
IVT Aflibercept Other Phase PHASE1 Diabetic Macular Edema COMPLETED NCT02949024
Sham Procedure Procedure Phase PHASE3 Uveitis COMPLETED NCT02595398
4mg CLS-TA Suprachoriodal Injection Other Phase PHASE3 Uveitis COMPLETED NCT02595398
Sham procedure Procedure Preclinical Uveitis COMPLETED NCT02952001
4 mg CLS-TA Suprachoriodal Injection Other Preclinical Uveitis COMPLETED NCT02952001
4 mg CLS-TA Suprachoriodal Injection Other Phase PHASE3 Uveitis COMPLETED NCT03097315
Anti-VEGF Other Phase PHASE1 Neovascular Age-related Macular Degeneration COMPLETED NCT04626128
CLS-AX Other Phase PHASE1 Neovascular Age-related Macular Degeneration COMPLETED NCT04626128
CLS-AX Other Preclinical Neovascular Age-related Macular Degeneration COMPLETED NCT05131646
Aflibercept DRUG Phase PHASE2 Neovascular Age-related Macular Degeneration COMPLETED NCT05891548
Anti-VEGF DRUG Phase PHASE1 Neovascular Age-related Macular Degeneration COMPLETED NCT04626128
CLS-AX DRUG Phase PHASE2 Neovascular Age-related Macular Degeneration COMPLETED NCT05891548
Lucentis or Avastin DRUG Phase PHASE3 Macular Edema TERMINATED NCT03203447
Sham SC DRUG Phase PHASE2 Diabetic Macular Edema COMPLETED NCT03126786
suprachoroidal sham DRUG Phase PHASE3 Macular Edema TERMINATED NCT03203447
suprachoroidal CLS-TA DRUG Phase PHASE3 Macular Edema TERMINATED NCT03203447
Sham procedure DRUG Preclinical Uveitis COMPLETED NCT02952001
4 mg CLS-TA Suprachoriodal Injection DRUG Phase PHASE3 Uveitis COMPLETED NCT03097315
SC CLS-TA DRUG Phase PHASE2 Diabetic Macular Edema COMPLETED NCT03126786
IVT Aflibercept DRUG Phase PHASE1 Diabetic Macular Edema COMPLETED NCT02949024
Sham Procedure DRUG Phase PHASE3 Uveitis COMPLETED NCT02595398
4mg CLS-TA Suprachoriodal Injection DRUG Phase PHASE3 Uveitis COMPLETED NCT02595398
IVT aflibercept DRUG Phase PHASE2 Diabetic Macular Edema COMPLETED NCT03126786
Sham DRUG Phase PHASE2 Macular Edema COMPLETED NCT02303184
0.8 mg CLS-TA DRUG Phase PHASE2 Uveitis COMPLETED NCT02255032
4 mg CLS-TA DRUG Phase PHASE2 Macular Edema COMPLETED NCT02303184
triamcinolone acetonide (Triesence®) DRUG Phase PHASE1 Uveitis COMPLETED NCT01789320
Total products: 45